Mineral deposition and vascular invasion of hydroxyapatite reinforced collagen scaffolds seeded with human adipose-derived stem cells by Weiss-Bilka, Holly E. et al.
RESEARCH ARTICLE Open Access
Mineral deposition and vascular invasion of
hydroxyapatite reinforced collagen
scaffolds seeded with human adipose-
derived stem cells
Holly E. Weiss-Bilka1, Matthew J. Meagher1, Joshua A. Gargac2, Glen L. Niebur1,3, Ryan K. Roeder1,3 and
Diane R. Wagner4*
Abstract
Background: Collagen-based scaffolds reinforced with hydroxyapatite (HA) are an attractive choice for bone tissue
engineering because their composition mimics that of bone. We previously reported the development of
compression-molded collagen-HA scaffolds that exhibited high porosity, interconnected pores, and mechanical
properties that were well-suited for surgical handling and fixation. The objective of this study was to investigate
these novel collagen-HA scaffolds in combination with human adipose-derived stem cells (hASCs) as a template for
bone formation in a subcutaneous athymic mouse model.
Methods: Collagen-HA scaffolds and collagen-only scaffolds were fabricated as previously described, and a clinically
approved bone void filler was used as a control for the material. Constructs were seeded with hASCs and were pre-
treated with either control or osteogenic media. A cell-free group was also included. Scaffolds were implanted
subcutaneously in the backs of athymic nude mice for 8 weeks. Mineral deposition was quantified via micro-
computed tomography. Histological and immunofluorescence images of the explants were used to analyze their
vascular invasion, remodeling and cellularity.
Results: Cell-free collagen-HA scaffolds and those that were pre-seeded with osteogenically differentiated hASCs
supported mineral deposition and vascular invasion at comparable rates, while cell-seeded constructs treated with
the control medium showed lower mineralization after implantation. HA-reinforcement allowed collagen constructs
to maintain their shape, provided improved cell-tissue-scaffold integration, and resulted in a more organized tissue
when pre-treated in an osteogenic medium. Scaffold type and pre-treatment also determined osteoclast activity
and therefore potential remodeling of the constructs.
Conclusions: The results of this study cumulatively indicate that treatment medium and scaffold composition
direct mineralization and angiogenic tissue formation in an ectopic model. The data suggest that it may be
necessary to match the scaffold with a particular cell type and cell-specific pre-treatment to achieve optimal bone
formation.
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Background
Non-union fractures and critical size bone defects have a
considerable impact upon the global population [1]. In
fact, bone is the second most transplanted tissue world-
wide with an estimated 2.2 million graft procedures per-
formed each year [2]. Yet despite their prevalence,
autogenic grafts are limited by the availability of donor
tissue and are often associated with donor site pain,
while allogenic grafting techniques carry the risk of mor-
bidity and infection [3]. These limitations have inspired
many research efforts involving laboratory-produced tis-
sue replacements; however current approaches to bone
tissue engineering generally lack a sufficient functionality
compared to native bone matrix.
Collagen-based scaffolds reinforced with hydroxyapa-
tite (HA) are an attractive choice for bone tissue engin-
eering because they mimic the key components of bone,
collagen and mineral, and possess improved mechanical
properties compared to either component alone [4, 5].
We previously reported novel compression-molded
collagen-HA scaffolds that exhibited high porosity (85–
90%), ~ 300–400 μm interconnected pores, struts com-
posed of high-density collagen fibrils reinforced with HA
whiskers, and mechanical properties that were well-
suited for surgical handling and fixation [6]. These scaf-
folds were also conducive to the infiltration and in vitro
differentiation of adipose-derived stem cells [6]. After
ectopic implantation, the vascular density, cell density,
matrix deposition, and micro-computed tomography
(micro-CT) bone volume increased with increasing HA
content in the scaffolds [7]. However, in these previous
studies, the collagen-HA scaffolds were implanted with-
out pre-seeding with osteogenic cells, which may further
increase bone tissue generation.
Human adult adipose-derived stem cells (hASCs)
are an appealing complement to such scaffolds be-
cause they are abundant and have been shown to
contribute to both bone formation and vasculogenesis
[8] in vivo. Subcutaneous implantation in immunode-
ficient mice is an established model for evaluating
combinations of hASCs with various scaffolds and
culture conditions, with multiple reports of successful
bone formation in the literature [9]. One of the earli-
est successful studies coupled β-tricalcium phosphate
discs with hASCs and then pre-treatment in an
osteoinductive medium for 2 weeks. During 8 weeks of
subcutaneous implantation in nude mice, the cell-
seeded discs developed an osteocalcin-rich tissue con-
taining osteoclasts and infiltrated by blood vessels
[10]. Another study reported bone formation in 4 of
5 HA-tricalcium phosphate (TCP) and in 1 of 5 Col-
lagraft® (collagen-HA-TCP composite matrix) scaffolds
that had been seeded with untreated hASCs and sub-
jected to 6 weeks subcutaneous implantation in nude
mice [11]. In a different investigation, hASCs seeded
onto porous HA ceramic scaffolds and cultured in a
3-D perfusion system for 5 days prior to subcutaneous
implantation in nude mice for 8 weeks resulted in
well vascularized constructs containing osteoprogeni-
tor cells and positive immunostaining for human
bone sialoprotein [12]. Interestingly, immunostaining
for human CD31 and CD34 indicated that newly
formed vessels were of human origin. More recently,
the importance of surface topography was demon-
strated in the context of TiO2 nanotube surfaces,
which enhanced the osteogenic differentiation of
hASCs both in vitro and in vivo [13]. Finally, hASCs
were first cultured on either extracellular matrix de-
rived from bone marrow-derived mesenchymal stem
cells or tissue culture plastic before being loaded on
HA powder and implanted subcutaneously in immu-
nodeficient mice; hASCs that had been expanded on
the cell-derived matrix produced more bone tissue
compared to those cultured on tissue culture plastic
[14].
The objective of this study was therefore to investigate
the use of novel collagen-HA (CHA) scaffolds in com-
bination with hASCs as a template for bone formation
in a subcutaneous athymic mouse model. Cell-seeded
constructs were pre-treated with either control medium
(CM), or an osteogenic medium (OM). A cell-free, or
acelluar (Acel), control group of collagen-HA scaffolds
was included to assess the osteoinductive capacity of the
scaffold itself. This group was cultured in OM for the
same duration as cell-seeded groups. The effect of HA
in the scaffold was examined by including a collagen-
only (Col) control group. Finally, NuOss™ (Nu) – a clin-
ically approved bone void filler previously reported to
support bone formation in ectopic models when coupled
with human periosteum-derived cells, human mesoan-
gioblasts and a murine pre-chondrogenic cell line [15,
16] – was included as a control for the scaffold material.
Methods
Cell culture
Human adipose-derived stem cells (ZenBio, Durham,
NC) derived and pooled from the subcutaneous adipose
tissue of 5 non-diabetic female donors were expanded as
previously described [17, 18]. During expansion, cells
were plated at a density of 3000 cells/cm2 and were
maintained in DMEM/F12 medium (MediaTech, Hern-
don, VA) containing 10% FBS (Atlas Biologicals, Fort
Collins, CO), 1% Penicillin-Streptomycin (Pen-Strep,
MediaTech), 5 ng/mL human epidermal growth factor
(hEGF), 1 ng/mL human fibroblast growth factor-2
(hFGF2) and 0.25 ng/mL transforming growth factor-β1
(TGF-β1) [19]; all growth factors from PeproTech,
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Rocky Hill, NJ). Cells were treated with fresh medium
every 2 days.
Scaffold preparation
Collagen (Col) and collagen with 40 vol% hydroxyapatite
whiskers (CHA) scaffolds with 85% porosity and a mean
pore size of ~ 375 μm were fabricated as previously de-
scribed [6, 7]. NuOss™ scaffolds were purchased from
Ace Surgical Supply (Brockton, MA). All scaffolds were
sized to 21mm3 (3 mm diameter × 3mm height) using a
sterile biopsy punch. After crosslinking and porogen
leaching of Col and CHA scaffolds, implants were steril-
ized by submersion in 70% ethanol and rehydrated in
sterile PBS followed by sterile culture medium supple-
mented with 1% Pen-Strep.
Cell seeding and in vitro culture
For cell seeding, pre-sterilized scaffolds were transferred
to a sterile gauze pad, where excess medium was re-
moved, and then to sterile, agarose-coated tissue culture
plates. Passage 7 hASCs were drop-seeded onto each
scaffold in a 20 μL suspension at a seeding density of
21 × 106 cells/mL and placed into a humidified incuba-
tor at 37 °C and 5% CO2 for 1 hour to attach. After 1
hour, 1 mL of either control medium (CM: DMEM-HG,
10% FBS, 1% Pen-Strep) or osteogenic differentiation
medium [10, 20] (OM: CM supplemented with 50 μg/
mL ascorbic acid, 10 mM β–glycerophosphate, 0.1 μM
dexamethasone; all additives from Sigma-Aldrich, St.
Louis, MO) was added to each construct. NuOss™ scaf-
folds, previously successful in inducing bone formation
with human periosteal-derived cells in an ectopic model
[15], were included as a control. These scaffolds are of
bovine origin and contain natural bone mineral in an
open collagen network. Preliminary studies demon-
strated that no bone was formed when this scaffold was
implanted without cells. Collagen-only (Col) scaffolds
were included to assess the contribution of HA whiskers
to bone formation, and the importance of pre-
implantation osteogenic induction was investigated by
treating seeded hASCs with OM compared to CM.
Following overnight incubation, the culture medium
was collected from each well containing a cell-seeded
scaffold and unattached cells were pelleted at 300×g, re-
suspended, and counted with a hemocytometer to deter-
mine seeding efficiency. Fresh culture medium was
added to all scaffolds three times per week for 14 days,
which is the time at which hASC monolayer cultures
have previously shown markers of osteogenic differenti-
ation in vitro [11, 20]. ALP activity and calcium nodules
were confirmed in cells grown in monolayer and treated
with OM and CM for 14 days. On the day of implant-
ation, 1 scaffold per group (see Table 1) was rinsed with
PBS, fixed overnight in 4% paraformaldehyde at 4 °C,
embedded in optimal cutting temperature (OCT) com-
pound and processed for histology.
Subcutaneous ectopic implantation in mice
Remaining scaffolds were implanted subcutaneously in
the cervical region of athymic nude mice (Harlan La-
boratories, Indianapolis, IN). All procedures were carried
out in compliance with protocols approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of
the University of Notre Dame. Mice were anesthetized
with a ‘rodent cocktail’ consisting of 100 mg/mL Keta-
mine, 20 mg/mL Xylazine and 10 mg/mL Acepromazine
(all from Henry Schein, Dublin, OH) in sterile saline, ac-
cording to the following dosage [6, 7]: Volume
anesthetic [μL] = (Body weight [g] × 10) – 50. Three
constructs from three different groups were implanted
in each mouse (five mice total) through a small incision
in the center of the dorsal region. Following 8 weeks of
implantation, mice were sacrificed and scaffolds were
recovered.
Micro-computed tomography of scaffolds and explants
Prior to cell seeding, all scaffolds to be implanted were
scanned by micro-CT (Bioscan NanoSPECT/CT, Mediso
Medical Imaging Systems, Budapest, Hungary) at 10 μm
resolution, 70 kVp voltage, 100 mA current with 720
projections at 600ms integration time. Micro-CT images
were median filtered to reduce noise. The bone volume
(BV) was measured by segmenting images at a threshold
of 1900, which corresponded to 294 mg HA/cm3 using a
custom calibration phantom [21]. An ex-vivo micro-CT
scan was performed on all explants after overnight fix-
ation in 4% paraformaldehyde, using the same parame-
ters as the pre-implantation scans. De novo
mineralization was measured by the difference in thre-
sholded BV between the implant and explant.
Table 1 Overview of experimental groups
Abbreviation Nu OM Col OM CHA Acel CHA CM CHA OM
Scaffold NuOss™ Collagen Collagen/HA Collagen/HA Collagen/HA
Calcium source CaP granules – HA whiskers HA whiskers HA whiskers
hASCs + + – + +
Medium OM OM OM CM OM
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Histology and immunofluorescence
Fixed samples were rinsed with PBS, decalcified in a 0.5
M EDTA solution and subjected to a series of increasing
concentrations of sucrose in PBS. Explants were equili-
brated in OCT compound (Sakura, Torrance, CA) for 3
h, frozen in dry ice-cooled isopentane, and stored at −
80 °C prior to sectioning. Each embedded sample was
cryosectioned at a thickness of 7–9 μm and transferred
to gelatin subbed slides, which were dried at 37 °C for 2
h and then stored at − 80 °C. Slides were warmed to
room temperature and dried prior to all staining proce-
dures. Sections were stained with H&E following stand-
ard histological techniques. Tartrate resistant acid
phosphatase (TRAP) staining was performed by 2 h in-
cubation in TRAP buffer (50 mM sodium acetate, 30
mM sodium tartrate, 0.1% Triton X-100, pH 5). The buf-
fer was then replaced with TRAP stain for 1 h before 2
rinses in PBS, counterstaining with hematoxylin and
mounting with aqueous mounting medium [16].
All immunofluorescence (IF) procedures were opti-
mized for the specific antibody. Unless otherwise noted,
IF procedures were performed for CD31 (R&D Systems;
10 μg/mL), osteopontin (OPN goat polyclonal, R&D Sys-
tems; 15 μg/mL), vascular endothelial growth factor
(VEGF rabbit polyclonal, Abcam; 1 μg/mL), osteocalcin
(OCN rabbit polyclonal, Abcam; 1:1000) as follows.
Slides were brought to room temperature, hydrated in
PBS and, when necessary, subjected to antigen retrieval
consisting of 5 min incubation at 90 °C in 1 mM EDTA,
0.05% Polysorbate-20, pH 8.0. Sections were cooled to
room temperature, rinsed with PBS, and blocked with
1% normal serum from the animal in which the second-
ary antibody was raised and 0.3M glycine in PBS for 30
min at room temperature. Primary antibody was applied
in blocking solution overnight at 4 °C. Slides were rinsed
with PBS before the secondary antibody (Alexa Fluor®
anti-goat IgG and anti-rabbit IgG, Invitrogen; 1:200) was
diluted in 1% BSA and applied for 1 h at room
temperature. Finally, sections were counterstained with
4′,6-Diamidino-2-Phenylindole (DAPI), rinsed with PBS,
and mounted in an aqueous medium.
For human nuclei antibody (HNA), sections were
brought to room temperature, permeabilized with ice
cold acetone for 10 min at room temperature, dried and
re-hydrated in PBS. Blocking was performed in two
steps: first with 3% normal donkey serum and 0.3M gly-
cine in PBS for 30 min, and then with Mouse IgG Block-
ing Reagent (Vector Labs, Burlingame, CA). Primary
antibody was applied (1:200, Mouse Monoclonal 235–1
IgG1, Rockland, Gilbertsville, PA) at room temperature
for 1 h, sections were rinsed with PBS, and the secondary
antibody was applied for 20 min at room temperature
(Alexa Fluor® 488 Donkey anti-mouse, Invitrogen; 1:
800). All nuclei were counterstained with DAPI (Vector
Labs), and endogenous fluorescence was quenched with
a 1 min Trypan blue incubation (250 μg/mL, pH 4.4,
Invitrogen, Grand Island, NY) [22]. Sections were rinsed
quickly with PBS, and mounted with aqueous medium.
Quantification and analysis
To quantify the extent of vascular invasion into each
group, 6 randomized images were taken from H&E-
stained sections of each scaffold. The number of vessels,
identified as lumina containing erythrocytes, was
counted for each image, and 18 images (6 per scaffold; 3
randomized images per section at 2 depths) were aver-
aged for each group and the number of vessels per mm2
were reported [23].
Cellularity was evaluated by quantifying the number of
cells in DAPI-stained sections. Images were taken at
central and peripheral radial locations of a given cross-
section, at shallow and mid-height depths for each con-
struct. The calculated number of cells from the center
and periphery of a given cross-section were summed
and normalized by the total imaged area to obtain a total
number of cells per mm2. Images were taken at 400X
magnification and processed in MATLAB (MathWorks,
Natick, MA) with CellC [24, 25], applying a segmenta-
tion factor of 0.9 and cell shape as the segmentation
modality.
Statistical analyses were performed in Prism (Graph-
Pad, La Jolla, CA). Significance was assessed by 1-way or
2-way ANOVA and Tukey’s post-hoc test (p < 0.05) as
appropriate. Data are presented as the mean ± SEM.
Results
Cell seeding and scaffold preparation
Following the initial attachment period and overnight in-
cubation, cell-containing constructs had a minimum
seeding efficiency of 99.33 ± 0.11% (Fig. 1a). Histological
analysis of scaffolds cultured for 14 days in vitro verified
cellular infiltration throughout all scaffold types and a
developing extracellular matrix in the pore spaces (Fig.
1b-e). Cells appeared to be more evenly distributed in
Col and CHA scaffolds compared to NuOss™ controls,
where cells were more densely populated around the
periphery of the scaffolds. NuOss™ (Fig. 1b) and Col (Fig.
1c) controls exhibited a non-circular cross-section and
volumetric shrinkage after 2 weeks of culture, whereas
CHA scaffolds cultured in either type of treatment
medium (Fig. 1d, e) maintained their original size and
shape.
Cells grown in monolayer and treated with OM and
CM stained positive for alkaline phosphatase activity and
contained small nodules of mineralization after 14 days
of induction (not shown). The intensity and incidence of
staining was higher for cells cultured with OM,
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indicating that this treatment was directing hASCs to-
ward an osteogenic lineage.
Tissue morphology and micro-CT analysis
Gross morphological evaluation revealed that Col and
CHA CM explants were noticeably smaller than im-
planted constructs, and NuOss™ constructs were white,
while all other groups had a light-pink tint (Fig. 2).
Blood vessels were most prominent on CHA OM and
CHA Acel explants; however, vessels were also visible in
CHA CM and Col explants. Interestingly, no blood ves-
sels were visible in the NuOss™ control group.
After 8 weeks implantation, explants exhibited varying
degrees of bone formation as determined by micro-CT.
Each group exhibited a significant change between pre-
implant (0 week) and post-explant (8 week) measurements
Fig. 1 Scaffold seeding efficiency and morphology after in vitro culture. a Scaffold seeding efficiency, one-way ANOVA (n = 4; p = 0.17). b-e
Representative H&E stained cryosections of hASC-seeded scaffolds after 14 days in culture. Note the composition of each scaffold by coloration:
dark red indicates calcium phosphate granules in NuOss™ scaffolds; red-orange indicates collagen; black indicates the presence of HA whiskers;
small, dark spots indicate cell nuclei; light pink indicates ECM deposited by hASCs; white space represents empty pore space
Fig. 2 Representative gross morphology of explants (a-e) after 8 weeks implantation
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of bone volume (Fig. 3a). NuOss™ controls decreased in
measured bone volume by 3.05 ± 0.55mm3. In contrast,
the bone volume of Col OM constructs increased from 0
to 1.06mm3, and CHA OM constructs increased in vol-
ume by 2.08 ± 0.21mm3. Interestingly, acellular CHA scaf-
folds increased in bone volume by 2.14mm3, while the
CHA CM constructs decreased by 2.40 ± 0.11mm3.
H&E stained sections revealed substantial differences in
tissue morphology among groups. Like pre-implantation
samples, the central region of NuOss™ scaffolds appeared
to be less cellular than the periphery, based upon the eosin
stain intensity (Fig. 3b). Tissue infiltration in Col scaffolds
(Fig. 3c) was not as dense as in the CHA scaffolds (Fig.
3d-f). CHA OM and CHA Acel scaffolds maintained a
well-defined porous structure, while the pore structure of
CHA CM and Col OM constructs appeared deformed and
partially collapsed. Any changes in the porosity of NuOss™
scaffolds were less clear, but a certain amount of scaffold
remodeling was apparent via tissue infiltration into the
calcium phosphate granules.
Higher magnification revealed the organizational
structure of the tissues within each group. Interestingly,
treatment medium appeared to elicit a distinct tissue
morphology and cellular response in hASC-seeded CHA
scaffolds. CHA CM constructs formed a dense, disorga-
nized tissue (Fig. 3e); whereas CHA OM constructs
produced a spatially organized tissue (Fig. 3f). In general,
the dense tissue observed in CHA OM constructs was
preferentially located around the periphery of pore
spaces and formed a ring-like structure around less
dense tissue in the center of the pores. The tissue within
CHA Acel constructs was similarly organized (Fig. 3d).
Dense, eosinophilic tissue was also observed at the edges
of tissue within pore space in Col OM constructs; how-
ever, there were typically gaps between this tissue and
the walls of the collagen struts (Fig. 3c).
Osteogenic and vasculogenic markers
Immunofluorescence staining revealed osteocalcin-
positive tissue located in the matrix of CHA Acel and
OM groups (Fig. 4c, e). Positive staining was also ob-
served to a lesser extent in NuOss™, Col and CHA CM
groups (Fig. 4a, b, d). Osteopontin immunofluorescence
was more intense for HA-containing constructs, and ap-
peared to localize to the scaffold structure (Fig. 4h-j).
Interestingly, the spatial patterning of osteopontin was
similar in NuOss™ and Col groups, though the staining
intensity was not as strong as in constructs that con-
tained HA (Fig. 4f, g).
Histological analysis revealed the degree of
vascularization for each group (Fig. 5). CHA OM con-
structs had a higher blood vessel count (23.0 ± 3.3
Fig. 3 Change in bone volume and tissue morphology after 8 weeks implantation. a Absolute change in bone volume as measured by micro-CT; one-
way ANOVA and Tukey’s post-hoc test (n = 3; p < 0.0001). Different letters indicate statistically significant differences. b-f Representative H&E stained
cryosections showing the entire scaffold cross-section (upper image) and new tissue within scaffold pore spaces at higher magnification (lower image)
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vessels/mm2) than CHA CM (13.8 ± 2.1 vessels/mm2)
and NuOss™ (5.0 ± 1.0 vessels/mm2) constructs. Col and
CHA Acel also had significantly more vessels than
NuOss™ scaffolds at 18.4 ± 1.8 and 16.8 ± 2.2 vessels per
mm2, respectively.
To better understand differences in vascularization,
VEGF levels in the cell-seeded scaffolds were also
visualized via immunofluorescence. Within in vitro con-
structs, hASCs were actively secreting VEGF after 14
days of culture (Fig. 6a-e, Pre-implant). Immunostaining
for VEGF was more apparent in OM groups at this time
point. Images of post-implantation constructs displayed
a different trend (Fig. 6f-j, Post-implant). CHA OM and
CHA Acel groups had a high level of intense staining,
Fig. 4 Osteogenic markers in explanted constructs. Representative immunostained sections showing (a-e) osteocalcin and (f-j) osteopontin after
8 weeks implantation. Red: osteocalcin or osteopontin; blue: DAPI (cell nuclei)
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while CHA CM constructs maintained a low level of
VEGF. Nu OM constructs, which exhibited levels of
VEGF staining comparable to CHA OM scaffolds after
in vitro culture, exhibited a marked decrease in VEGF
expression after 8 weeks of implantation. Staining was
similar at both time points for the Col OM group; how-
ever, the intensity of the stain was lower than that of
CHA Acel and CHA OM groups after 8 weeks of
implantation.
Osteoclast activity and cellularity
Tartrate-resistant acid phosphatase (TRAP) staining
demonstrated that there was considerable osteoclast ac-
tivity in CHA CM constructs (Fig. 7). Positive activity
was also identified on the periphery of NuOss™ and, to a
lesser extent, CHA OM explants. No staining was de-
tected in Col or CHA Acel groups.
The cellularity of each explant was also evaluated
(Fig. 8a). Comparing cell counts from the cross-sections
sampled, the number of cells in constructs cultured
in vitro for 14 days was not statistically different (Fig.
8b). However, following 8 weeks in vivo, NuOss™ ex-
plants contained fewer cells and CHA CM explants con-
tained more cells than all other groups (Fig. 8b), with 8
week NuOss™ explants containing approximately the
same number of cells as the 14 days in vitro time point.
The cell distribution of evaluated cross-sections was not
significantly different for Col OM and CHA CM con-
structs; however, the number of cells quantified at the
center of CHA OM cross-sections was lower than at the
periphery for in vitro scaffolds and for 8 week constructs
(Fig. 8b). Unlike NuOss™ explants, however, the cellular-
ity of the CHA OM group increased by a factor of 4.5
following implantation.
Human nuclei immunofluorescence was used in con-
junction with DAPI to evaluate the donor cell contribu-
tion to new tissue formation in explants. Human cells
were identified within the implanted construct in all
Fig. 5 Vascularization after 8 weeks implantation. a Blood vessel density; one-way ANOVA and Tukey’s post-hoc test (n = 18; p < 0.05). Different
letters indicate statistically significant differences. b-f Representative H&E stained cryosections showing blood vessels (black arrows). (G-K)
Representative immunofluorescent stained sections showing CD31 (red) with DAPI counterstain (blue). White arrows denote blood vessels. (L)
CD31 (red) and DAPI (blue) immunofluorescent staining overlaid on a matched bright field image showing the presence of erythrocytes within
the vessel lumen
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cell-seeded scaffold types (Fig. 9); however, few remained
after 8 weeks of implantation. The hASCs detected were
primarily located on the periphery of the scaffolds or in
the surrounding tissue. Additionally, despite physical
separation within the mice, a single hASC was detected
in the surrounding tissue of a CHA Acel explant (data
not shown).
Discussion
The results of this study cumulatively indicate that treat-
ment medium and scaffold composition direct
mineralization and angiogenic tissue formation in an ec-
topic model. One important effect of HA reinforcement
in collagen-based carriers was evident after only 14 days
of culture in vitro. All constructs with CHA scaffolds
Fig. 6 VEGF levels before and after implantation. Representative sections showing VEGF (red) and cell nuclei (blue) (a-e) after 14 days of in vitro
culture but before implantation and (f-j) after 8 weeks implantation
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maintained the original size and circular cross-section
throughout the pre-treatment period, whereas NuOss™
and collagen scaffolds exhibited volumetric shrinkage
into an irregular, oblong-like shape. This finding sug-
gests that HA whisker reinforcement increased the
structural stability of collagen-based scaffolds through-
out in vitro culture.
In terms of mineralization, the mineral content mea-
sured by micro-CT was increased in cell-seeded CHA
scaffolds with pre-treatment in OM, but the increase
was not significantly different from that in acellular
CHA scaffolds. Similar results have been observed previ-
ously for other osteoinductive scaffolds [26, 27]. Lyons
et al. reported that matrix deposited by MSCs during
in vitro culture may adversely affect healing by acting as
a barrier to macrophage-mediated remodelling when im-
planted in vivo [28]. The current study confirms previ-
ous reports that the CHA scaffolds alone promote the
recruitment and osteogenic activity of endogenous cell
populations [6, 7]. Additionally, ASC-seeded NuOss™
Fig. 7 Osteoclast activity in explanted constructs (a-e). Representative TRAP-stained sections showing osteoclast activity (red)
Fig. 8 Cell distribution in scaffolds pre- and post-implantation. a Scaffold cross-section stained with DAPI. b Radial distributions of cells in in vitro
samples (14d, n = 3) and 8 week explants (8w, n = 6). * indicates a significant difference between the periphery (black) and center (white) of
individual scaffold groups (p < 0.05). ## indicates a significant increase in total cell number compared to 14d groups and 8w Nu OM (p < 0.001).
Letters indicate that cell number for periphery (p) or center (c) significantly increased from 14d to 8w (p < 0.05)
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scaffolds exhibited a decrease in bone volume, suggest-
ing that any bone formation was insufficient to counter-
balance the resorption of the scaffold. Collectively, these
data suggest that a combination of cell type and pre-
treatment may need to be determined for a particular
scaffold to achieve optimal bone regeneration.
While pre-treatment of hASC-seeded CHA scaffolds
in OM resulted in significant increases in mineralization,
pre-treatment in CM resulted in decreased mineral con-
tent. This may be a result of the high osteoclastic activity
observed via TRAP staining in the CHA CM scaffolds
(Fig. 7d). As opposed to mature osteoblasts, pre-
osteoblasts have been reported to express higher levels
of RANKL, which allows for the maturation, differenti-
ation and activation of osteoclasts [29]; this may explain
the high osteoclast activity in the scaffolds with undiffer-
entiated cells in the current study. Osteoclast activity
can be a positive indicator of scaffold resorption; how-
ever, the rate of resorption must be balanced with the
deposition of replacement tissue and the maintenance of
mechanical integrity.
To better characterize the tissue infiltrating the scaf-
folds, two bone markers were investigated: osteocalcin, a
marker of osteoblasts that is associated with mineralized
bone matrix; and osteopontin, a non-collagenous protein
that is secreted by osteoblasts, osteocytes and osteoclasts
and is therefore believed to play a role in both
mineralization and bone remodeling [30]. Qualitatively,
there was more osteopontin in CHA constructs than in
collagen and NuOss™ scaffolds after 8 weeks of subcuta-
neous implantation. Localization of this protein to the
scaffold structure is likely due to its ability to bind HA
[30], and may account for the spatial organization of the
tissue within CHA Acel and CHA OM groups. The ma-
jority of dense, bone-like matrix indicated by highly eo-
sinophilic tissue (Fig. 3) and concentrated osteocalcin
staining (Fig. 4) was identified at the periphery of the
pore spaces in these constructs. HA may be at least par-
tially responsible for this effect, as gaps were observed
between the collagen-only scaffold and the extracellular
matrix in the pores, and osteopontin levels were lower
in these scaffolds.
Following implantation, the level of vascular invasion
was higher in Col OM and CHA OM groups compared
with CHA CM constructs, indicating that osteogenic
pre-treatment may have contributed to this effect. Inter-
estingly, CHA Acel controls achieved levels of
vascularization comparable to CHA OM and Col OM
constructs, while NuOss™ controls contained signifi-
cantly fewer vessels. A similar trend was observed in
VEGF levels: staining was stronger for CHA OM than
for CHA CM, and there was considerably less VEGF de-
tected in Nu OM constructs. VEGF, which is generally
thought of as a key mediator of angiogenesis [31], also
Fig. 9 Detection of human cells within explanted constructs (a-e). Representative immunofluorescent stained sections showing human nuclei
antigen (green) and cell nuclei counterstained with DAPI (blue) overlaid on a matched bright field image demonstrating the location of cells
within the scaffolds. Blood vessels appear in red. The locations of magnified inset regions are indicated by black dotted lines
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has the ability to regulate the recruitment and activity of
osteoblasts, osteoclasts, and endothelial cells [32]. There-
fore, higher levels of VEGF detected in CHA OM com-
pared to CHA CM constructs both pre- and post-
implantation may partially explain the differential
mineralization and vascular invasion between these
groups.
The tissue organization observed in CHA Acel and
OM constructs was not maintained in CHA CM or Col
OM tissues in the current study (Figs. 1 and 3). For
CHA CM scaffolds, this may be a result of the high
osteoclastic activity observed via TRAP staining (Fig. 7).
The collapsed architecture apparent in the CHA CM
group, along with a high level of osteoclast activity, were
indicative of rapid resorption in these scaffolds. De-
creased tissue organization in Col OM scaffolds could
also be the result of collapsed pore structure, likely an
effect of the absence of HA.
The decreased mineral content observed in NuOss™
scaffolds may be a result of its inhibited cellular infiltra-
tion compared to other groups. This is likely related to
their 9% lower porosity compared to Col and CHA scaf-
folds, as reported by the manufacturer. The
eosinophilic-rich, VEGF-, osteocalcin- and osteopontin-
positive tissue in this group was observed only at the
scaffold periphery, where the cell density was highest.
This region coincided with the location of observed
blood vessels and osteoclast activity. Conversely, the
central region had a very low cell density both pre- and
post-implantation, and bone markers were not detected
in this area. Previous studies with hASCs have reported
that cell density has a significant impact upon resulting
tissue formation [33], indicating that a lower concentra-
tion of cells at the scaffold center may have influenced
its bone forming capacity.
Despite significant differences in vascularity,
mineralization and cellularity in cell-seeded groups, few
human cells were identified in any of the explants.
Remaining hASCs were primarily located at the periph-
ery of the scaffold, or in the surrounding tissue, perhaps
indicating their migration out of the constructs. This hy-
pothesis is supported by the detection of a human cell in
the tissue surrounding an acellular construct. Both re-
tention [33] and loss [34] of ASCs has been reported in
the literature, introducing further confusion regarding
their role in ectopic bone formation.
Conclusions
The results of this study indicate that both scaffold type
and pre-treatment are crucial to successful mineral de-
position and vascular invasion, and that to achieve opti-
mal mineralization it may be necessary to match the
scaffold with a particular cell type and cell-specific pre-
treatment. HA-reinforcement allowed collagen
constructs to maintain their implanted shape, provided
for improved cell-tissue-scaffold integration, and re-
sulted in a more organized tissue when pre-treated in an
osteogenic induction medium.
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